The company today announced a key addition to the management team at its Singapore facilities. AMRI named a new director of in vitro biology, Saravanakumar Dhakshinamoorthy, Ph.D., who will report directly to Takesi Yura, Ph.D., the senior director of AMRI Singapore. As leader of all the company’s biology resources in Singapore, Dr. Dhakshinamoorthy will be working on projects closely with his colleagues in the United States and India.
AMRI’s Singapore research center provides a full spectrum of drug discovery services to the pharmaceutical and biotechnology industries. Its capabilities support all the different sciences required to discover and advance new small molecule medicines. Some of these sciences include medicinal chemistry, in vitro biology, and DPMK (drug metabolism and pharmacokinetics). Preclinical drug candidates found this way are advanced by access to the company’s global development services.
Dr. Dhakshinamoorthy brings to AMRI more than 20 years of postgraduate experience in academic and industrial settings. He comes to the company after seven years with Aurigene, a discovery services company in Bangalore, India, and he also did work previously in Singapore with the Institute of Molecular and Cell Biology.
For additional information about Albany Molecular Research and the services it offers, please visit the company’s website at www.amriglobal.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
